Fibrous adhesion of the intestine overcome by Oncostatin M gene therapy.

通过制瘤素 M 基因治疗克服肠道纤维粘连。

• 批准号: 20599019
• 负责人: HAMADA Tetsuhiro
• 金额: $ 2.44万
• 依托单位: Hyogo College of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20599019/
• 关键词: Oncostatin M; Gene therapy; 炎症; Gene thrapy

By irradiation for abdominal malignancies, normal bowel into the irradiated area by bring radiation enteritis and fibrosis, abdominal pain, bloody diarrhea and causes. The applicant, a rat model of liver injury in Oncostatin M (OSM) gene therapy trial, OSM found that the effect of anti-inflammatory and anti-fibrosis (Am J Pathol. 171 : 872-881, 2007). In this study, the intestinal tract of animal models of fibrosis gene to OSM, examined for intestinal fibrosis intestinal epithelium OSM examined the usefulness of gene therapy. OSM gene was found in the treated group was suppressed by the failure of the intestinal tract compared with the control group. OSM suggesting the possibility that inhibition of fibrosis by anti-inflammatory effect.

因腹部恶性肿瘤经放射线照射后，正常肠道进入照射区而引起放射性肠炎及纤维化、腹痛、血性腹泻等原因。申请人对大鼠肝损伤模型进行了Oncostatin M（OSM）基因治疗试验，发现OSM的抗炎和抗纤维化作用（Am J Pathol. 171：872-881，2007）。本研究通过对肠道纤维化动物模型进行基因导入OSM，检验了OSM对肠上皮细胞肠纤维化基因治疗的实用性。与对照组相比，治疗组的OSM基因受肠道功能衰竭的抑制。提示OSM可能通过抗炎作用抑制纤维化。